EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Jingxin Zhidong Formula Alleviates Tic Disorder via Modulation of Microglial IKK/NF‐κB Signaling and Striatal Neurotransmitter Homeostasis

Fei Fan iD, Jing Yang, Zenghui Niu, Chengkui Xiu iD, Fei Han

Brain and Behavior · 2026

DOI: 10.1002/brb3.71361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2026. Verfasst von Fei Fan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, NF-kappa B, I-kappa B Kinase, Microglia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Public Welfare Research Institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tic disorder (TD) is a neurodevelopmental condition for which pharmacological treatments are limited and are frequently associated with side effects. Jingxin Zhidong formula (JXZDF) offers a potential alternative therapy; however, its mechanism of action has not been fully elucidated. This study investigated the therapeutic effects of JXZDF on TD and explored underlying mechanisms involving neurotransmitter regulation and microglial IκB kinase/nuclear factor‐κB (IKK/NF‐κB) signaling, a pathway implicated in both inflammatory activation and metabolic reprogramming.

Methods

A TD rat model was established using 3,3'‐iminodipropionitrile (IDPN). Rats were treated with low‐, medium‐, or high‐dose JXZDF or aripiprazole for three weeks, after which behavioral scores were assessed. Histology, immunohistochemistry, quantitative reverse transcription‐polymerase chain reaction, western blotting (WB), and enzyme‐linked immunosorbent assay (ELISA) analyses of striatal tissue were performed to evaluate neuronal morphology, neurotransmitter receptor expression (N‐methyl‐D‐aspartate receptor subunit 1 [NMDAR1], glutamate receptor 1 [GRIA1], gamma‐aminobutyric acid type A receptor α1 subunit [GABAARα1], and gamma‐aminobutyric acid type A receptor β2 subunit [GABAAβ2]), as well as glutamate and GABA levels. The IKK/NF‐κB pathway was examined both in vivo and in lipopolysaccharide‐stimulated BV‐2 microglial cells using WB, immunofluorescence, and ELISA, with the IKKβ inhibitor IMD‐0354 used for mechanistic validation.

Results

JXZDF treatment significantly reduced abnormal behavioral scores in the TD rat model in a dose‐dependent manner. Treatment ameliorated striatal neuronal damage and corrected the neurotransmitter imbalance by specifically reducing glutamate and increasing the expression of excitatory receptors (NMDAR1, α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors [AMPAR], and glutamate receptor subunit 1 [GluA1]), while increasing GABA and inhibitory receptor expression (GABAARα1 and GABAAβ2). JXZDF also suppressed IKK/NF‐κB pathway activation in the striatum of TD rats and in LPS‐activated BV‐2 cells, as evidenced by reduced IκBα and NF‐κB p65 phosphorylation, inhibited NF‐κB p65 nuclear translocation, and decreased pro‐inflammatory cytokine (interleukin‐6 [IL‐6], tumor necrosis factor‐alpha [TNF‐α]) secretion. The anti‐inflammatory and neuroprotective effects of JXZDF were reversed by co‐treatment with IMD‐0354.

Conclusions

JXZDF alleviated tic‐like behaviors in a TD rat model by restoring striatal excitatory‐inhibitory neurotransmitter balance and inhibiting microglial‐mediated neuroinflammation. Its therapeutic effect was at least partially mediated by suppression of IKK/NF‐κB. These findings provide a pharmacological basis for the clinical application of JXZDF in TD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalNF-kappa BI-kappa B KinaseMicrogliaCorpus StriatumAnimalsSignal TransductionRatsRats, Sprague-DawleyMaleDisease Models, AnimalHomeostasisNeurotransmitter Agents

Stichwörter der Autor:innen

GABAGlutamateIKK/NF‐κB pathwayJingxin Zhidong Formulamicroglianeuroinflammationtic disorder

Substanzen

Drugs, Chinese HerbalNF-kappa BI-kappa B KinaseNeurotransmitter Agents

Autor:innen und Institutionen

  • Department of Paediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.

ORCID-Profile: Fei Fan, Chengkui Xiu

Förderung

  • Fundamental Research Funds for the Central Public Welfare Research Institutes

Zitieren

APA

Fan, F., Yang, J., Niu, Z., Xiu, C., & Han, F. (2026). Jingxin Zhidong Formula Alleviates Tic Disorder via Modulation of Microglial IKK/NF‐κB Signaling and Striatal Neurotransmitter Homeostasis. Brain and Behavior. https://doi.org/10.1002/brb3.71361

Vancouver

Fan F, Yang J, Niu Z, Xiu C, Han F. Jingxin Zhidong Formula Alleviates Tic Disorder via Modulation of Microglial IKK/NF‐κB Signaling and Striatal Neurotransmitter Homeostasis. Brain and Behavior. 2026. doi:10.1002/brb3.71361

BibTeX
@article{Fan2026,
  author = {Fan, Fei and Yang, Jing and Niu, Zenghui and Xiu, Chengkui and Han, Fei},
  title = {Jingxin Zhidong Formula Alleviates Tic Disorder via Modulation of Microglial IKK/NF‐κB Signaling and Striatal Neurotransmitter Homeostasis},
  journal = {Brain and Behavior},
  year = {2026},
  doi = {10.1002/brb3.71361}
}
Kostenlos starten →